BioSpace News Archive

NuVasive, Inc. announced today that Chief Executive Officer Chris Barry will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m. PT.

Karyopharm Therapeutics Inc. today announced updated results from the Phase 1 portion of its study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389).

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC, dated December 9, 2022, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Capital Market’s rules for continued listing (the “Notice”).

Gamida Cell Ltd. announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”).

Lumos Pharma, Inc. hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD).

Genomic Biopharma Inc. has partnered with Associazione Poic e Dintorni APS to enable access to whole genome sequencing (WGS) and demonstrate the utility of genomic information to treat and cure the most severe disorders of gut motility.

Today, Quest Diagnostics (NYSE: DGX) released its latest Health Trends ® report, “Drug Misuse in America 2022: A Decade Lost to the Drug Crisis.”

Syros Pharmaceuticals today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy.

Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naive.

Clovis Oncology, Inc. announced that it and certain of its subsidiaries have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware and will seek to sell their assets through a court supervised sales process.